The US FDA has approved four COVID vaccines targeting the XFG variant for the 2026-2027 season, developed by Moderna, Pfizer and BioNTech, Novavax, and Sanofi. While the vaccines are available for high-risk individuals, the CDC’s lack of guidance leads to… Read More »FDA approves four new COVID vaccines for the 2026-27 season
Recent developments indicate promising long-term results from clinical trials for an mRNA vaccine targeting pancreatic cancer, a notoriously hard-to-diagnose and treat disease. This individualized vaccine stimulates an immune response against cancer cells and may enhance patient outcomes when used in… Read More »Pancreatic cancer mRNA vaccine showing long-term success
The FDA has approved four COVID-19 vaccines for Fall 2025, including mRNA options from Moderna and Pfizer, and Novavax’s non-mRNA vaccine. Eligibility is primarily for individuals 65 and older, or 64 and younger with high-risk conditions. Healthcare providers may not… Read More »2025 COVID-19 vaccines FAQs — important questions answered
Rumors regarding HHS Secretary RFK Jr’s intent to eliminate COVID vaccines have surfaced, but the FDA approved new versions for Fall 2025. While vaccines are available for all individuals 65 and older, those under 64 must have high-risk conditions to… Read More »FDA approves Fall 2025 COVID vaccines with restrictions
HHS Secretary RFK Jr. has canceled over $500 million in mRNA vaccine funding, jeopardizing future vaccine development amidst ongoing health crises like bird flu. His anti-mRNA stance contradicts scientific evidence, risking delays in vital research. This decision threatens public health… Read More »RFK Jr cancels $500 million funding of mRNA vaccine research
A recent study examined the relationship between Guillain-Barré syndrome (GBS) and COVID vaccines. It found a 310% increased risk of GBS post-adenoviral vector vaccination, while mRNA vaccines reduced this risk. Notably, GBS risk from COVID infection was higher. Claims linking… Read More »COVID vaccines and the risk of Guillain-Barré syndrome
BioNTech’s pancreatic cancer mRNA vaccine candidate, cevumeran, has shown promising results in a phase 1 trial, offering hope in cancer treatment. Individualized to each patient, it enhances immune response post-surgery and may prevent recurrence. A forthcoming phase 2 trial aims… Read More »Pancreatic cancer mRNA vaccine — exciting clinical trial results
As children return to school, it’s vital to vaccinate against RSV, seasonal flu, and COVID for fall 2024. RSV, with new vaccines approved, poses risks especially to infants and older adults. Seasonal flu and updated COVID vaccines also remain crucial.… Read More »Which vaccines should you get for Fall 2024?
BioNTech has announced early promising results for their new lung cancer mRNA vaccine candidate, BNT116. This vaccine works by presenting specific antigens to the immune system, activating immune cells to target cancer cells. Currently in phase 2 trials, it could… Read More »Lung cancer mRNA vaccine shows promising results
Pfizer and BioNTech’s phase 3 trial for their combination flu and COVID-19 mRNA vaccine did not meet one of its main goals, specifically non-inferiority against the influenza B strain. The companies are evaluating next steps, discussing results with regulatory agencies,… Read More »Flu COVID vaccine misses a goal of phase 3 clinical trial